Alexza's Adasuve wins European approval
This article was originally published in Scrip
Executive Summary
The European Commission has given the thumbs up for Alexza's schizophrenia and bipolar disorder drug Adasuve (loxapine) to be marketed in the EU.
You may also be interested in...
Spain's Ferrer To Rescue Floundering US Biotech Alexza
US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.